Oncoclinicas do Brasil Servicos Medicos SA
BOVESPA:ONCO3
Oncoclinicas do Brasil Servicos Medicos SA
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Oncoclínicas do Brasil Serviços Médicos SA operates as a holding company, which engages in oncology clinics through the health care segment. The company is headquartered in Sao Paulo, Sao Paulo. The company went IPO on 2021-08-10. The firm provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The firm holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Strategic Restructuring: Oncoclinicas executed a major organizational turnaround in Q3, selling three general hospitals and exiting noncore assets to focus on oncology.
Capital Raise: The company completed a capital increase of approximately BRL 1.4 billion, significantly deleveraging its balance sheet.
EBITDA Margin Recovery: Adjusted EBITDA rose to BRL 241 million, with EBITDA margin expanding by 450 basis points to 17.1%.
Profitability Improvement: Gross margin (cash margin) grew to 32.3%, up 200 basis points sequentially, with further improvements expected as noncore hospital operations wind down.
Revenue Impact: Net revenue decreased 3.5% quarter-over-quarter, mainly due to the loss of the Unimed FERJ contract, but management noted strong replacement of lost revenue from other clients.
Working Capital & Cash: Organic free cash flow was BRL 62.4 million, and working capital improved significantly, with net capital days dropping by 16 days sequentially.
Guidance & Outlook: Management expects continued deleveraging, margin expansion, and double-digit revenue growth in 2024, without large CapEx needs.
Asset Write-offs: Substantial noncash write-offs and provisions, including BRL 466.2 million for hospital assets and BRL 864 million for doubtful debt, impacted reported results but are considered nonrecurring.
